The Top 5 Biosimilar Articles for the Week of May 31

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of May 31, 2021.

Number 5: BioFactura has begun a phase 1 clinical trial for an ustekinumab biosimilar candidate (BFI-751) referencing Stelara, an immunosuppressant for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

Number 4: More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.

Number 3: Investigators reporting on insulin availability in the Philippines said affordability and access are inadequate for many in the country and recommended measures for improvement.

Number 2: Febrile neutropenia (FN) in patients undergoing chemotherapy has long been counteracted with granulocyte colony-stimulating factor (G-CSF) drugs. Models of G-CSF biosimilar use in this setting suggest not only significant savings but also potential for expanded access.

Number 1: Biosimilar manufacturers may encounter roadblocks in the months and years ahead, and generics manufacturers will find they've hit a ceiling, according to Adam Fein, PhD, CEO of the Drug Channels Institute.

To read all of these articles and more, visit centerforbiosimilars.com.